ZOMETA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZOMETA (ZOMETA).
Zoledronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), thereby preventing the prenylation of small GTPase signaling proteins essential for osteoclast activity.
| Metabolism | Zoledronic acid is not metabolized and is excreted unchanged primarily by the kidneys via glomerular filtration and tubular secretion. |
| Excretion | Renal: 50-60% of the dose excreted unchanged in urine within 24 hours; terminal elimination involves slow release from bone with subsequent renal excretion; biliary/fecal excretion is minimal (<5%). |
| Half-life | Terminal elimination half-life is approximately 146 hours (6.1 days) due to prolonged release from bone; clinical context: supports monthly dosing for osteoporosis and quarterly for Paget's disease. |
| Protein binding | Approximately 22-33% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is 0.8-1.0 L/kg, indicating extensive distribution into bone and soft tissues; clinical meaning: large Vd reflects high bone affinity. |
| Bioavailability | Intravenous: 100% (only route of administration); oral bioavailability is negligible (<5%) due to poor absorption and binding to dietary calcium. |
| Onset of Action | Intravenous infusion: Reduction in bone resorption markers (e.g., NTX) observed within 24-48 hours; clinical effect on hypercalcemia occurs within 2-4 days. |
| Duration of Action | Bone resorption suppression persists for up to 3 weeks after a single dose; clinical effect on hypercalcemia may last 7-14 days; repeat dosing typically every 4 weeks for osteoporosis. |
| Molecular Weight | 388.13 |
4 mg IV over 15 minutes every 3-4 weeks for hypercalcemia of malignancy or bone metastases.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in CrCl <35 mL/min. For CrCl 35-60 mL/min: reduce dose to 3 mg. No adjustment needed for CrCl >60 mL/min. |
| Liver impairment | No specific dose adjustments for hepatic impairment. Use caution in severe hepatic impairment. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; monitor renal function and electrolytes closely due to age-related decline in renal function. |
| 1st trimester | Contraindicated due to risk of fetal harm; animal studies show developmental toxicity and adverse effects on fetal bone development. Use only if clearly needed and no safer alternative. |
| 2nd trimester | Avoid; potential skeletal and renal effects on fetus. Consideration only if maternal benefit outweighs fetal risk, with close monitoring. |
| 3rd trimester | Avoid; risk of neonatal hypocalcemia and potential skeletal abnormalities. Not recommended unless essential for maternal condition. |
Clinical note
Comprehensive clinical and safety monograph for ZOMETA (ZOMETA).
| Placental transfer | Zoledronic acid crosses the placenta in animal studies; human data are limited but suggest transfer occurs. Binding to bone mineral may result in accumulation in fetal skeleton. |
| Breastfeeding | Excreted in human milk in low amounts; effects on infant are unknown. Because of potential for serious adverse reactions (e.g., hypocalcemia, renal toxicity), caution should be exercised. Consider temporary cessation of breastfeeding during and for a period after treatment. |
■ FDA Black Box Warning
Renal toxicity: Zometa has been associated with renal toxicity, particularly in patients with pre-existing renal impairment or when used in conjunction with other nephrotoxic drugs. Osteonecrosis of the jaw (ONJ): Increased risk with invasive dental procedures and longer treatment duration.
| Common Effects | Diarrhea Nausea Vomiting Flatulence |
| Serious Effects |
Hypersensitivity to zoledronic acid or any bisphosphonateHypocalcemiaSevere renal impairment (CrCl <35 mL/min)Pregnancy (unless clearly needed)
| Precautions | Monitor renal function before and during therapy; assess serum creatinine. Osteonecrosis of the jaw: perform dental exam before treatment. Atypical femur fractures: evaluate for thigh or groin pain. Hypocalcemia: correct before initiation. Severe musculoskeletal pain. Not recommended in severe renal impairment (CrCl <35 mL/min). |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe; avoid if possible, especially in preterm or neonatal infants) |
| Teratogenic Risk | ZOMETA (zoledronic acid) is contraindicated in pregnancy. Based on animal studies and its mechanism of action (bisphosphonate), there is potential for fetal harm. In the first trimester, there may be risk of skeletal and organ abnormalities due to inhibition of bone resorption. In second and third trimesters, fetal bone development may be impaired, leading to hypocalcemia, skeletal retardation, and low birth weight. Human data are limited; however, bisphosphonates cross the placenta and accumulate in fetal bone. |
| Fetal Monitoring | Monitor serum calcium, phosphate, magnesium, and creatinine before and during infusion. Assess renal function regularly. Measure fetal growth via ultrasound if inadvertent exposure in pregnancy. Monitor for maternal hypocalcemia and osteomalacia. In fetuses, monitor for skeletal abnormalities and hypocalcemia. |
| Fertility Effects | Zoledronic acid may impair fertility. In animal studies, high doses caused reduced fertility and preimplantation losses in rats. In humans, no formal studies; but bisphosphonates can cause ovarian toxicity and potentially reduce fertility. Advise women of reproductive potential to use effective contraception during therapy and for a period after discontinuation. |
| Zometa has no direct food interactions, but adequate calcium and vitamin D intake is essential to prevent hypocalcemia. Avoid excessive intake of calcium-rich foods or supplements without medical supervision, as hypercalcemia can occur in certain conditions. |
| Clinical Pearls | Zometa (zoledronic acid) is a bisphosphonate that inhibits osteoclast-mediated bone resorption. Administer intravenously over at least 15 minutes to reduce renal toxicity. Monitor serum creatinine before each dose; hold if renal function worsens. Assess for hypocalcemia, especially in patients with vitamin D deficiency; supplement calcium and vitamin D routinely. Risk of osteonecrosis of the jaw (ONJ) increases with dental procedures; perform dental exam before therapy. Acute phase reaction (fever, myalgia) is common after first dose; premedicate with acetaminophen or NSAIDs. |
| Patient Advice | This medication is given as an infusion into a vein and requires regular blood tests to check kidney function. · You should have a dental check-up before starting treatment to reduce the risk of jaw problems. · Common side effects include fever, muscle aches, and flu-like symptoms after the first dose; these usually resolve within a few days. · Take calcium and vitamin D supplements as recommended by your doctor to prevent low calcium levels. · Report any unusual pain, swelling, or numbness in your jaw, teeth, or mouth immediately. · Drink plenty of fluids before and after infusion to protect your kidneys. · Avoid dental procedures while on this medication unless absolutely necessary and discussed with your doctor. |